1. Home
  2. ETY vs NAMS Comparison

ETY vs NAMS Comparison

Compare ETY & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETY
  • NAMS
  • Stock Information
  • Founded
  • ETY 2006
  • NAMS 2019
  • Country
  • ETY United States
  • NAMS Netherlands
  • Employees
  • ETY N/A
  • NAMS N/A
  • Industry
  • ETY Finance Companies
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ETY Finance
  • NAMS Health Care
  • Exchange
  • ETY Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • ETY 2.5B
  • NAMS 2.7B
  • IPO Year
  • ETY N/A
  • NAMS N/A
  • Fundamental
  • Price
  • ETY $15.86
  • NAMS $27.00
  • Analyst Decision
  • ETY
  • NAMS Strong Buy
  • Analyst Count
  • ETY 0
  • NAMS 10
  • Target Price
  • ETY N/A
  • NAMS $41.40
  • AVG Volume (30 Days)
  • ETY 247.3K
  • NAMS 872.1K
  • Earning Date
  • ETY 01-01-0001
  • NAMS 08-06-2025
  • Dividend Yield
  • ETY 7.21%
  • NAMS N/A
  • EPS Growth
  • ETY N/A
  • NAMS N/A
  • EPS
  • ETY N/A
  • NAMS N/A
  • Revenue
  • ETY N/A
  • NAMS $64,006,000.00
  • Revenue This Year
  • ETY N/A
  • NAMS N/A
  • Revenue Next Year
  • ETY N/A
  • NAMS N/A
  • P/E Ratio
  • ETY N/A
  • NAMS N/A
  • Revenue Growth
  • ETY N/A
  • NAMS 762.15
  • 52 Week Low
  • ETY $10.59
  • NAMS $14.06
  • 52 Week High
  • ETY $13.46
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • ETY 55.93
  • NAMS 67.63
  • Support Level
  • ETY $15.60
  • NAMS $24.41
  • Resistance Level
  • ETY $15.94
  • NAMS $25.65
  • Average True Range (ATR)
  • ETY 0.16
  • NAMS 1.10
  • MACD
  • ETY 0.01
  • NAMS 0.05
  • Stochastic Oscillator
  • ETY 72.58
  • NAMS 98.63

About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: